The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Myeloproliferative Neoplasms: In Detail
- In August 2026, the Food and Drug Administration (FDA) approved rusfertide (Mimrylo™) for the treatment of erythrocytosis in adults with polycythemia vera (PV).
- In August 2026, the Food and Drug Administration (FDA) expanded the indication of ropeginterferon alfa-2b-njft (Besremi®) to include the treatment of adults with essential thrombocythemia.
Blood Cancer United resources
Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.
